PLoS ONE (Jan 2021)

Optimal treatment strategies for stage I non-small cell lung cancer in veterans with pulmonary and cardiac comorbidities.

  • Keith Sigel,
  • Chung Yin Kong,
  • Sadiq Rehmani,
  • Susan Bates,
  • Michael Gould,
  • Kimberly Stone,
  • Minal Kale,
  • Yeun-Hee Park,
  • Kristina Crothers,
  • Faiz Bhora,
  • Juan Wisnivesky

DOI
https://doi.org/10.1371/journal.pone.0248067
Journal volume & issue
Vol. 16, no. 3
p. e0248067

Abstract

Read online

BackgroundVeterans are at increased risk of lung cancer and many have comorbidities such as chronic obstructive pulmonary disease (COPD) and coronary artery disease (CAD). We used simulation modeling to assess projected outcomes associated with different management strategies of Veterans with stage I non-small cell lung cancer (NSCLC) with COPD and/or CAD.Patients and methodsUsing data from a cohort of 14,029 Veterans (years 2000-2015) with NSCLC we extended a well-validated mathematical model of lung cancer to represent the management and outcomes of Veterans with stage I NSCLC with COPD, with or without comorbid CAD. We simulated multiple randomized trials to compare treatment with lobectomy, limited resection, or stereotactic body radiation therapy (SBRT). Model output estimated expected quality adjusted life years (QALY) of Veterans with stage I NSCLC according to age, tumor size, histologic subtype, COPD severity and CAD diagnosis.ResultsFor Veterans ConclusionsThe harm/benefit ratio of treatments for stage I NSCLC among Veterans may vary according to COPD severity and the presence of CAD. This information can be used to direct future research study design for Veterans with stage I lung cancer and COPD and/or CAD.